Nektar Therapeutics
NKTR
265 hedge funds and large institutions have $9.21B invested in Nektar Therapeutics in 2017 Q4 according to their latest regulatory filings, with 84 funds opening new positions, 69 increasing their positions, 96 reducing their positions, and 20 closing their positions.
475% more call options, than puts
Call options by funds: $183M | Put options by funds: $31.8M
320% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 20
149% more capital invested
Capital invested by funds: $3.69B → $9.21B (+$5.51B)
75% more funds holding in top 10
Funds holding in top 10: 8 → 14 (+6)
31% more funds holding
Funds holding: 203 → 265 (+62)
0.01% less ownership
Funds ownership: 6.56% → 6.56% (-0.01%)
28% less repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 96
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$423M |
| 2 |
PC
PointState Capital
New York
|
+$92.5M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$79.7M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$78.8M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
+$40.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
-$401M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$72.9M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$65.2M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
-$52.8M |
| 5 |
BM
Bridger Management
New York
|
-$35.8M |
NKTR Hedge Fund Activity: Q4 2017 in Review
265 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q4 2017, worth a combined $9.21B — up 149% from $3.69B a quarter earlier.
Buyers outnumbered sellers: 84 funds opened new NKTR positions and 20 closed out — a net gain of 64 holders — while 69 added to existing stakes and 96 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $423M. The largest seller was OppenheimerFunds, cutting an estimated $401M.
- 265 institutional investors held Nektar Therapeutics (NKTR) as of Q4 2017, up from 203 in Q3 2017.
- Funds reported $9.21B of Nektar Therapeutics stock for Q4 2017, up 149% quarter-over-quarter.
- 84 funds opened new Nektar Therapeutics positions in Q4 2017 and 20 closed out, a net change of +64 holders.
- The largest Nektar Therapeutics buyer in Q4 2017 was Fidelity Investments, an estimated $423M added.
- The largest Nektar Therapeutics seller in Q4 2017 was OppenheimerFunds, an estimated $401M sold.
Based on aggregated 13F filings for Q4 2017.